Stock AnalizIllumina, Inc. ILMN
Medical Specialities · IPO 2000 · data as of November 13, 2026
Illumina, Inc. (ILMN) is a healthcare company listed in the US with a market value of about $31.3B. In the twelve months to September 27, 2026 it had revenue of $4.5B and net income of $895M, a net margin of 19.7%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 35.6, a price to free cash flow of 29.6, 5-year revenue growth of 6% a year, a 5-year average ROIC of -10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
Score: 1.8 / 5
Checks passed
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5B | $4.3B | $4.4B | $4.5B | $4.6B | $4.5B | $3.2B | $3.5B | $3.3B | $2.8B | $2.4B |
| Net income | $895M | $850M | -$1.2B | -$1.2B | -$4.4B | $762M | $656M | $1.0B | $826M | $726M | $463M |
| Free cash flow | $1.1B | $931M | $709M | $283M | $106M | $337M | $891M | $842M | $846M | $565M | $519M |
| EPS (diluted) | $5.81 | $5.45 | $-7.69 | $-7.34 | $-28.00 | $5.04 | $4.45 | $6.74 | $5.56 | $4.92 | $3.07 |
| Net margin | 19.7% | 19.6% | -28.0% | -25.8% | -96.1% | 16.8% | 20.2% | 28.3% | 24.8% | 26.4% | 19.3% |
| ROIC | — | 12.0% | -13.2% | -10.5% | -35.1% | -0.9% | 6.7% | 13.4% | 11.9% | 10.0% | 13.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 20 analysts is $261.45, 26% above the current price; targets range from $165.00 to $365.00; the consensus rating is “Buy”; expected EPS is $5.48 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Illumina’s P/E ratio?
About 35.6, based on the last twelve months of diluted earnings per share (forward P/E about 34.7).
Is Illumina stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Illumina pay a dividend?
Not currently.
Is Illumina a good stock to buy?
We do not give buy or sell advice. Illumina scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.